-Scroll.in RTIs filed by Scroll.in show complaints about enrolling agencies demanding bribes and doing fraud enrolments. On Wednesday, the Unique Identification Authority of India said that it had blacklisted the enrolment agency that had inadvertently leaked details of former Indian cricket team captain MS Dhoni’s application to join the Aadhaar programme. The day before, Dhoni’s wife Sakshi had sent a tweet to Information and Technology Minister Ravi Shankar Prasad informing him of...

-NDTV In his maiden appearance after being named Uttar Pradesh chief minister, Yogi Adityanath proclaimed that his Bharatiya Janata Party (BJP) government would maintain a laser-like focus on the twin themes of combating corruption and restoring law and order. "In the past 15 years," Adityanath noted, "UP lagged behind in the race of development as previous governments indulged in corruption, nepotism, and failed on the law order front." Indeed, one of...

-Frontline.in Recently released data from the CSO, which claimed that demonetisation had had no significant impact on the performance of the economy, raise more questions than provide answers. Official data released by the Central Statistical Organisation (CSO) on the last day of February, which claimed that the national gross domestic product (GDP) rose by 7 per cent in the October-December period, the third quarter of 2016-17, came as a morale booster...

-TheWire.in The Department of Personnel and Training, responsible for implementing the RTI, has claimed it is exempt from sharing details on the appointment of information commissioners. New Delhi: When it comes to transparency, it seems the Narendra Modi government is moving in reverse. The Department of Personnel and Training, the nodal agency responsible for effectively implementing the Right to Information (RTI) Act, has refused to share details on the appointment of information...

-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s...